GSTM1 and paroxysmal nocturnal hemoglobinuria: The phase 3 open-label PEGASUS trial, which compared the efficacy and safety of pegcetacoplan with eculizumab for the treatment of PNH in patients already receiving eculizumab, reported ΔBL Hb level to week 16 as the primary endpoint [37].